for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Infinity Pharmaceuticals Inc.

INFI.OQ

Latest Trade

2.00USD

Change

0.19(+10.50%)

Volume

87,550

Today's Range

1.81

 - 

2.00

52 Week Range

0.60

 - 

2.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.81
Open
1.81
Volume
87,550
3M AVG Volume
12.99
Today's High
2.00
Today's Low
1.81
52 Week High
2.17
52 Week Low
0.60
Shares Out (MIL)
64.21
Market Cap (MIL)
128.41
Forward P/E
-3.05
Dividend (Yield %)
--

Next Event

Q4 2020 Infinity Pharmaceuticals Inc Earnings Release

Latest Developments

More

Infinity Pharma Reports Q3 Loss Per Share Of $0.16

Infinity Pharmaceuticals Expects Net Loss For 2020 To Range From $35 Million To $45 Million

Infinity Pharmaceuticals Reports Q1 Loss Per Share Of $0.19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Infinity Pharmaceuticals Inc.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry

Biotechnology & Drugs

Contact Info

1100 Massachusetts Ave Ste 4

CAMBRIDGE, MA

02138-5241

United States

+1.617.4531000

http://www.infi.com

Executive Leadership

Adelene Q. Perkins

Chairman of the Board, Chief Executive Officer

Lawrence E. Bloch

President, Treasurer

Seth A. Tasker

Senior Vice President, Chief Business Officer and Secretary

Norman C. Selby

Lead Independent Director

Samuel Agresta

Director

Key Stats

2.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.830

2018

-0.200

2019

-0.830

2020(E)

-0.656
Price To Earnings (TTM)
--
Price To Sales (TTM)
80.66
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-94.35
Return on Equity (TTM)
-77.82

Latest News

Latest News

BRIEF-Infinity - Stockholders Approved To Increase Number Of Authorized Shares Of Common Stock To 200 Mln Shares

* INFINITY PHARMACEUTICALS - STOCKHOLDERS APPROVED AMENDMENT TO INCREASE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK TO 200 MILLION SHARES Source text for Eikon: https://bit.ly/2BjIMtW Further company coverage:

BRIEF-Infinity Pharmaceuticals Reports Q1 Loss Per Share Of $0.19

* Q1 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA

BRIEF-Infinity Pharmaceuticals Provides COVID-19 Update

* INFINITY PHARMACEUTICALS PROVIDES UPDATE IN RESPONSE TO COVID-19 PANDEMIC

BRIEF-Infinity Receives Fast Track Designation For IPI-549 In Combination With The Checkpoint Inhibitor Opdivo For The Treatment Of Advanced Urothelial Cancer

* INFINITY RECEIVES FAST TRACK DESIGNATION FOR IPI-549 IN COMBINATION WITH THE CHECKPOINT INHIBITOR OPDIVO FOR THE TREATMENT OF ADVANCED UROTHELIAL CANCER

BRIEF-Infinity Pharmaceuticals Expects Net Loss For 2020 Between $40 Mln And $50 Mln

* INFINITY PHARMACEUTICALS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Infinity To Initiate Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

* INFINITY TO INITIATE MARIO-3, A PHASE 2 MULTI-ARM STUDY EVALUATING IPI-549 IN FRONT-LINE TRIPLE NEGATIVE BREAST CANCER AND RENAL CELL CANCER

BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

* Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S

BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

* INFINITY PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, DILUTED LOSS PER COMMON SHARE WAS $0.18 - SEC FILING

BRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing

* INFINITY PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 1.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text: (https://bit.ly/2HF2NcI) Further company coverage:

BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10

* BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING

BRIEF-Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14​

* INFINITY PHARMACEUTICALS PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up